HIV drugs which only need to be taken once a month are to be developed at the University of Liverpool in a bid to overcome the problem of ‘pill fatigue’.
Using patients’ genetic material to help attack their particular version of HIV.
ViiV Healthcare’s single-tablet regimen Triumeq won Food and Drug Administration approval on August 22, 2014. Triumeq is the first FDA-approved single-tablet regimen (STR) that does not contain tenofovir (Viread), a widely used antiretroviral drug linked with bone and kidney problems in some susceptible HIV-positive individuals.
A meta-analysis of HIV patients in China shows strong relationship between didanosine-based treatments and increase in drug resistance.
A World Health Organisation (WHO) working group has called for the scrapping of so-called “homosexuality-related psychological disorders”.
With PEPFAR planning to shift about $100 million in HIV funding from South Africa to poorer countries, the New York Times reports, the country will face stern challenges in maintaining its AIDS effort.
Tivicay, the recently approved HIV integrase inhibitor — a class of antiretroviral drug that is designed to block a virus from entering the DNA of a host cell — demonstrated high rates of viral suppression in a recent study. Significantly, Tivicay is also proven effective for people who are resistant to HIV antiretroviral drugs, according to NAM.
Be heard! Share your experiences and be counted in this global survey on the health and human rights of gay men and other men who have sex with men (MSM)!